Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
Autolus Therapeutics (Nasdaq: AUTL), an early commercial stage biopharmaceutical company focused on programmed T cell therapies, has scheduled its Q4 and full year 2024 financial results announcement for March 20, 2025, before US markets open.
The company will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT where management will present financial results and provide a business update. Participants must pre-register to receive dial-in numbers and a personal PIN for the conference call. A simultaneous audio webcast and replay will be available on the company's website events section.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase commerciale iniziale focalizzata sulle terapie con cellule T programmate, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 20 marzo 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:30 EDT/12:30 GMT, durante la quale il management presenterà i risultati finanziari e fornirà un aggiornamento aziendale. I partecipanti devono registrarsi in anticipo per ricevere i numeri di accesso e un PIN personale per la conferenza telefonica. Una trasmissione audio simultanea e una registrazione saranno disponibili nella sezione eventi del sito web dell'azienda.
Autolus Therapeutics (Nasdaq: AUTL), una empresa biofarmacéutica en etapa comercial temprana centrada en terapias con células T programadas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 20 de marzo de 2025, antes de la apertura de los mercados en EE.UU.
La empresa llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:30 am EDT/12:30 pm GMT, donde la dirección presentará los resultados financieros y proporcionará una actualización del negocio. Los participantes deben registrarse previamente para recibir los números de acceso y un PIN personal para la llamada de conferencia. Una transmisión de audio simultánea y una repetición estarán disponibles en la sección de eventos del sitio web de la empresa.
Autolus Therapeutics (Nasdaq: AUTL)는 프로그램된 T 세포 치료에 중점을 둔 초기 상업 단계의 생명공학 회사로, 2025년 3월 20일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 이는 미국 시장 개장 전에 이루어질 것입니다.
회사는 동부 표준시 기준 오전 8시 30분/그리니치 표준시 기준 오후 12시 30분에 경영진이 재무 결과를 발표하고 비즈니스 업데이트를 제공하는 전화 회의 및 웹캐스트를 주최합니다. 참가자는 전화 회의에 대한 다이얼인 번호와 개인 PIN을 받기 위해 사전 등록해야 합니다. 동시에 오디오 웹캐스트와 재생본이 회사 웹사이트의 이벤트 섹션에서 제공될 예정입니다.
Autolus Therapeutics (Nasdaq: AUTL), une entreprise biopharmaceutique en phase commerciale précoce axée sur les thérapies par cellules T programmées, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 20 mars 2025, avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 EDT/12h30 GMT, où la direction présentera les résultats financiers et fournira une mise à jour sur les activités. Les participants doivent s'inscrire à l'avance pour recevoir les numéros d'appel et un code PIN personnel pour la conférence téléphonique. Une diffusion audio simultanée et un enregistrement seront disponibles dans la section événements du site web de l'entreprise.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der frühen kommerziellen Phase, das sich auf programmierte T-Zelltherapien konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 auf den 20. März 2025 vor der Eröffnung der US-Märkte angesetzt.
Das Unternehmen wird um 8:30 Uhr EDT/12:30 Uhr GMT eine Telefonkonferenz und einen Webcast veranstalten, bei der das Management die finanziellen Ergebnisse präsentieren und ein Update zum Geschäft geben wird. Teilnehmer müssen sich im Voraus registrieren, um die Einwahlnummern und eine persönliche PIN für die Telefonkonferenz zu erhalten. Eine gleichzeitige Audioübertragung und eine Wiederholung werden im Veranstaltungsbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025.
Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
When will Autolus Therapeutics (AUTL) release its Q4 2024 earnings?
What time is the AUTL Q4 2024 earnings conference call?
How can investors access AUTL's Q4 2024 earnings call?
What will be discussed in AUTL's upcoming earnings call?
